Brief: AcuCort: ISICORT Does Not Meet Bioequivalence Requirements For US Registration
Oct 15 (Reuters) - AcuCort AB ACUC.TE :
* BIOEQUIVALENCE WAS NOT ACHIEVED IN SECOND STUDY FOR US
REGISTRATION
* IN CURRENT STUDY ISICORT MET BIOEQUIVALENCE REQUIREMENTS
ON TWO
OF THREE CRITERIA
* WILL NOW ANALYZE OUTCOME WITH AIM OF IDENTIFYING MEASURES
NEEDED
TO MEET THE US CRITERIA
Source text for Eikon: ID:nWkr5H8Nds
Further company coverage: ACUC.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on AcuCort AB
See all newsBrief: Acucort Plans To Apply For U.S. Market Approval For Zeqmelit In 2026
Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Brief: Acucort AB Acucort Receives Marketing Authorization For Drug Zeqmelit By Norwegian Medicines Agency
Brief: Acucort Receives Marketing Authorization For The Drug Zeqmelit By The Danish Medicines Agency
Brief: AcuCort Is Granted Sme Status By The European Medicines Agency, EMA